FDA-Selected Kidney Disease Devices Still In Early Development
This article was originally published in The Gray Sheet
Executive Summary
Investigational devices from CreatiVasc Medical, Blood Purification Technologies and the University of California, San Francisco were selected for CDRH’s “innovation pathway 2.0” program.
You may also be interested in...
CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices
Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.
CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices
Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.
CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices
Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.